8551 related articles for article (PubMed ID: 22395592)
1. A lupus-like reaction to subcutaneous interferon-α at injection sites.
Chodkiewicz HM; Cohen PR; Kim KB; Ivan D; Gershenwald JE
J Drugs Dermatol; 2012 Mar; 11(3):393-8. PubMed ID: 22395592
[TBL] [Abstract][Full Text] [Related]
2. Lupus-like reaction to interferon at the injection site: report of five cases.
Arrue I; Saiz A; Ortiz-Romero PL; Rodríguez-Peralto JL
J Cutan Pathol; 2007 Dec; 34 Suppl 1():18-21. PubMed ID: 17997732
[TBL] [Abstract][Full Text] [Related]
3. Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
Zonta E; Chiarion V; Zarian H; Peserico A; Alaibac M
Melanoma Res; 2012 Jun; 22(3):284-5. PubMed ID: 22543678
[No Abstract] [Full Text] [Related]
4. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
Hashimoto Y; Kanto H; Itoh M
J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
[TBL] [Abstract][Full Text] [Related]
5. [Persistent inflammatory reaction at the injection site of Il-2 with lymphoma-like inflammatory infiltrates].
Assmann K; Nashan D; Grabbe S; Luger TA; Metze D
Hautarzt; 2002 Aug; 53(8):554-7. PubMed ID: 12221472
[TBL] [Abstract][Full Text] [Related]
6. [Cutaneous necrosis due to injection of interferon-alpha 2b in a patient with chronic hepatitis C].
Castellanos González M; Pérez Carreras M; Muñoz Gómez R; Castellano Tortajada G
Gastroenterol Hepatol; 2011 Oct; 34(8):584-5. PubMed ID: 21641684
[No Abstract] [Full Text] [Related]
7. [Vitiligo and morphea: autoimmune cutaneous side effects of interferon treatment].
Martínez-García S; Fernández-Ballesteros MD; Segura-Palacios JM
Actas Dermosifiliogr; 2012 Apr; 103(3):250-1. PubMed ID: 22056259
[No Abstract] [Full Text] [Related]
8. [Cutaneous necrosis due to interferon alpha in a patient with melanoma].
Aguilar García G; Serrano Falcón C; Serrano Falcón Mdel M; Carmona MD; Linares Solano J; Serrano Ortega S
Actas Dermosifiliogr; 2006 Oct; 97(8):539-42. PubMed ID: 17067536
[TBL] [Abstract][Full Text] [Related]
9. Delayed wound healing following treatment with low-dose interferon alfa-2b for cutaneous melanoma.
Ammoury AF; El Sayed F; Bazex J
Arch Dermatol; 2007 Oct; 143(10):1339-40. PubMed ID: 17938359
[No Abstract] [Full Text] [Related]
10. Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
Degen A; Weichenthal M; Ugurel S; Trefzer U; Kilian K; Garbe C; Egberts F; Poppe LM; Hauschild A; Gutzmer R
J Dtsch Dermatol Ges; 2013 Sep; 11(9):846-53. PubMed ID: 23879405
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
12. Lupus erythematosus-like skin eruption after vemurafenib therapy.
Reinholz M; Berking C; Hermans C; Ruzicka T; Braun-Falco M
J Am Acad Dermatol; 2014 Oct; 71(4):e159-60. PubMed ID: 25219748
[No Abstract] [Full Text] [Related]
13. Interferon α-induced lupus-like reaction in a mycosis fungoides patient: A case report.
Fatemi Naeini F; Yazdanpanah M; Mohaghegh F; Rajabi P; Tabatabaei ET
Int J Clin Pharmacol Ther; 2022 Jul; 60(7):306-310. PubMed ID: 35603683
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma.
Andrès P; Cupissol D; Guillot B; Avril MF; Drèno B
Eur J Dermatol; 1998 Jun; 8(4):235-9. PubMed ID: 9649695
[TBL] [Abstract][Full Text] [Related]
16. Local blistering reaction complicating subcutaneous injection of pegylated interferon in a patient with hepatitis C.
Gallina K; Brodell RT; Naffah F; Nedorost S
J Drugs Dermatol; 2003 Jan; 2(1):63-7. PubMed ID: 12852384
[TBL] [Abstract][Full Text] [Related]
17. Acute rhabdomyolysis as a complication of interferon treatment for stage IIIc melanoma.
Gavigan G; McEvoy A; Young V
J Cutan Med Surg; 2014; 18(4):277-9. PubMed ID: 25008446
[TBL] [Abstract][Full Text] [Related]
18. Severe cutaneous reactions following interferon injections.
Azagury M; Pauwels C; Kornfeld S; Bataille N; Perie G
Eur J Cancer; 1996 Sep; 32A(10):1821. PubMed ID: 8983299
[No Abstract] [Full Text] [Related]
19. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up.
Rusciani L; Proietti I; Paradisi A; Rusciani A; Guerriero G; Mammone A; De Gaetano A; Lippa S
Melanoma Res; 2007 Jun; 17(3):177-83. PubMed ID: 17505263
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment.
Solti M; Berd D; Mastrangelo MJ; Sato T
Melanoma Res; 2007 Aug; 17(4):225-31. PubMed ID: 17625452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
